CCDC102B: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: CCDC102B

NCBI ID: G79839

CCDC102B: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by progressive lung airflow limitation and persistent dyspnea. It is a type of chronic obstructive pulmonary disease that includes chronic bronchitis and emphysema. The pathogenesis of COPD mainly involves bronchospasm, mucus hypersecretion, airway inflammation, and lung tissue destruction. At present, the treatment of COPD mainly includes drug treatment, individualized treatment and control of risk factors. However, morbidity and mortality from COPD remain high, and this is an area where better treatments for the disease are needed.

In recent years, scientists have discovered some genes and molecular mechanisms related to COPD. Among them, CCDC102B is a gene related to COPD, which plays an important role in the development and progression of COPD. CCDC102B is a gene encoding a transcription factor-binding receptor and is a long non-coding RNA (lncRNA). It is upregulated in COPD patients and plays an important role in disease progression.

The role and significance of CCDC102B

CCDC102B is a gene related to COPD. Through functional research and clinical application of this gene, the molecular mechanism of COPD can be revealed and new targets and ideas for the treatment of COPD can be provided.

First, CCDC102B is a potential drug target. Studies have found that CCDC102B can be used as a biomarker and drug target for the treatment of COPD patients. Through drug intervention targeting CCDC102B, the symptoms and lung function of COPD can be improved, and the morbidity and mortality of COPD can be reduced.

Secondly, CCDC102B is an important biomarker. Through gene expression analysis of COPD patients, it can be found that CCDC102B plays an important role in the development and progression of COPD. In addition, the expression level of CCDC102B is also related to the severity and progression of the disease. Therefore, by detecting the expression level of CCDC102B, the severity and disease progression of COPD can be evaluated, and personalized treatment plans can be provided for the treatment of COPD.

Biological functions and clinical applications of CCDC102B

CCDC102B is a COPD-related gene that plays an important role in the occurrence and development of COPD. Through research, it has been found that activation of CCDC102B can lead to symptoms and pathophysiological changes of COPD.

First, activation of CCDC102B leads to bronchoconstriction and increased mucus secretion. These physiological changes can lead to symptoms such as dyspnea, cough, and sputum production in COPD patients, seriously affecting the patient's quality of life and health.

Secondly, activation of CCDC102B can also lead to airway inflammation. Airway inflammation can lead to airway spasm, edema, and cell infiltration, aggravating the symptoms and pathophysiological changes of COPD.

Third, activation of CCDC102B leads to lung tissue destruction. Long-term airway inflammation and bronchospasm can lead to lung tissue damage and diffuse lung damage, ultimately contributing to the severity and progression of COPD.

Therefore, CCDC102B is an important biological marker and therapeutic target. Through drug intervention targeting CCDC102B, the symptoms and lung function of COPD can be improved, and the morbidity and mortality of COPD can be reduced.

Protein Name: Coiled-coil Domain Containing 102B

Functions: During interphase, forms fibers at the proximal ends of centrioles to maintain centrosome cohesion (PubMed:30404835). During mitosis, dissociates from the centrosome following phosphorylation to allow centrosome separation (PubMed:30404835). Contributes to CROCC/rootletin filament formation (PubMed:30404835)

More Common Targets